Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 8,717 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 8,717 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $4.91, for a total value of $42,800.47. Following the transaction, the insider directly owned 580,329 shares of the company’s stock, valued at $2,849,415.39. The trade was a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total value of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total transaction of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total transaction of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total value of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.

Clene Trading Down 5.4%

Shares of NASDAQ:CLNN opened at $4.91 on Thursday. The firm has a market cap of $53.27 million, a price-to-earnings ratio of -1.45 and a beta of 0.87. The stock’s 50-day moving average price is $6.54 and its two-hundred day moving average price is $6.54. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. As a group, research analysts forecast that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Institutional Trading of Clene

Large investors have recently bought and sold shares of the company. Lunt Capital Management Inc. raised its stake in shares of Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares during the period. Jones Financial Companies Lllp acquired a new stake in Clene during the 3rd quarter valued at $29,000. Jane Street Group LLC purchased a new stake in Clene during the 2nd quarter worth $47,000. Finally, Scoggin Management LP increased its stake in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after buying an additional 42,750 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene News Summary

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Analysts give a fresh consensus “Moderate Buy” rating, which could support the stock if sentiment or fundamentals improve. Article Title
• Neutral Sentiment: There are conflicting short?interest reports in late January showing “0 shares” on some dates (likely data errors). This creates short?interest data uncertainty for traders relying on up?to?date borrow/cover signals.
• Negative Sentiment: Major shareholder Chidozie Ugwumba sold a total of ~19,274 CLNN shares across Jan. 26–28 (sales of 6,418 @ $5.02, 4,139 @ $5.08 and 8,717 @ $4.91), netting roughly $96k and reducing his stake. Insider selling of this size from a >10% holder often signals near?term selling pressure. SEC filing: SEC Filing
• Negative Sentiment: Short interest jumped earlier in January — as of Jan. 15 there were 752,820 shares short (up 45.7% from Dec. 31), representing ~10.7% of the float and a ~5.5 days?to?cover. Elevated short interest can accelerate downward moves and increase volatility if negative catalysts persist.

Analyst Ratings Changes

CLNN has been the topic of several research reports. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Finally, D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Clene presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).